2018 Protein Expression Protein Production Therapies 
The Pharma Data
JANUARY 16, 2021
Etta Biotech”), to set up a high titer transient protein expression platform for high quality protein production using JS Bio’s transient transfection media. JS Bio becomes the exclusive cell culture supplier for Etta Biotech’s transient transfection high titer protein expression platform.
Drug Discovery World
APRIL 30, 2024
Reece Armstrong explores the potential and future opportunities for mRNA-based therapies. For instance, consider how at the end of 2018, the mRNA therapies market was valued at $3.43 mRNA-based approaches can produce proteins / peptides by using protein synthesis which is processed in a transfected cell 1.
Expert insights. Personalized for you.
52 
Let's personalize your content